Combining chemotherapy with TKIs has been extensively studied in EGFR mutant lung adenocarcinoma, with FLAURA 2 study demonstrating overall survival benefit when used in the frontline setting and MARIPOSA-2 study in the second line setting, respectively [21,22]. This evidence concerns the gene EGFR and lung adenocarcinoma.